By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – UK phosphoproteomics firm Activiomics today announced it has received a £500,000 ($806,715) investment, which it will use to further build partnerships with pharmaceutical and biotech firms and to identify novel biomarkers.

Leading the round was IP Group. Additional investors included IP Venture Fund and members of Activiomics' management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.